{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:04:53Z","timestamp":1790535893590,"version":"4.1.0"},"reference-count":18,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec id=\"s1\"><jats:title>Objective<\/jats:title><jats:p>To assess satisfaction with the effectiveness and tolerability of treatments in patients with rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec id=\"s2\"><jats:title>Methods<\/jats:title><jats:p>Patients from the RABBIT register, starting a biological (b) or targeted synthetic (ts) disease-modifying antirheumatic drug (DMARD), or a conventional synthetic (cs)DMARD treatment after \u22651 csDMARD failure, were included. Treatment satisfaction was measured after 1 year of treatment in four categories and binarised for analysis. Logistic regression models were performed to calculate ORs for factors associated with treatment satisfaction.<\/jats:p><\/jats:sec><jats:sec id=\"s3\"><jats:title>Results<\/jats:title><jats:p>Data of 10\u00a0646 patients (74% women, mean 58\u00a0years) were analysed. At baseline, 55% of the patients were satisfied with the efficacy and 68% with the tolerability of their previously given treatments. After 1 year, 85% of the patients were satisfied with treatment effectiveness and 90% with tolerability. Baseline satisfaction (OR 2.98, 95% CI 2.58 to 3.44), seropositivity (OR 1.36, 95% CI 1.17 to 1.57), reduction of DAS28 (OR 1.38, 95% CI 1.31 to 1.46) and pain (OR 1.26, 95% CI 1.22 to 1.31), and the improvement of physical capacity (OR 1.22, 95% CI 1.17 to 1.29) were positively associated with treatment satisfaction at follow-up while glucocorticoids (GCs) &gt;5 mg\/day, depression, fibromyalgia, obesity, prior bDMARDs and therapy changes were negatively associated. The impact of GC on satisfaction was dose-dependent, becoming strongest for GC &gt;15 mg (OR 0.24, 95% CI 0.16 to 0.34). A 5 mg\/day reduction within 12\u00a0months was positively associated with satisfaction regarding efficacy (OR 1.19, 95% CI 1.11 to 1.27) and tolerability (OR 1.11, 95% CI 1.03 to 1.21).<\/jats:p><\/jats:sec><jats:sec id=\"s4\"><jats:title>Conclusion<\/jats:title><jats:p>Most patients were satisfied with their treatment\u2019s effectiveness and tolerability after 1 year of treatment. Tapering GCs was positively associated with the improvement of patients\u2019 satisfaction.<\/jats:p><\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001290","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T13:30:36Z","timestamp":1602595836000},"page":"e001290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6487-3634","authenticated-orcid":false,"given":"Martin","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-0294","authenticated-orcid":false,"given":"Katinka","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Kekow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Rockwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Liebhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7072-9022","authenticated-orcid":false,"given":"Angela","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-022X","authenticated-orcid":false,"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"2020101306300487000_6.3.e001290.1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/PPA.S5835","article-title":"Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy","volume":"3","author":"Barton","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"2020101306300487000_6.3.e001290.2","doi-asserted-by":"crossref","unstructured":"Smolen JS , Landewe RBM , Bijlsma JWJ , et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020. doi: 10.1136\/annrheumdis-2019-216655","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2020101306300487000_6.3.e001290.3","doi-asserted-by":"crossref","unstructured":"Bartlett SJ , De Leon E , Orbai AM , et al. Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results. Rheumatology (Oxford) 2019. doi: 10.1093\/rheumatology\/kez506","DOI":"10.1093\/rheumatology\/kez506"},{"key":"2020101306300487000_6.3.e001290.4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40744-019-0156-4","article-title":"Shared decision-making and patient satisfaction in Japanese rheumatoid arthritis patients: a new \u201cpreference fit\u201d framework for treatment assessment","volume":"6","author":"Mahlich","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2020101306300487000_6.3.e001290.5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/acr.23329","article-title":"Patients\u2019 attitudes and experiences of disease-modifying antirheumatic drugs in rheumatoid arthritis and spondyloarthritis: a qualitative synthesis","volume":"70","author":"Kelly","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020101306300487000_6.3.e001290.6","doi-asserted-by":"crossref","unstructured":"Calvo-Alen J , Vela P , Bustabad S , et al. Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. Rheumatol Clin 2018. doi: 10.1016\/j.reuma.2018.02.015","DOI":"10.1016\/j.reuma.2018.02.015"},{"key":"2020101306300487000_6.3.e001290.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.21985"},{"key":"2020101306300487000_6.3.e001290.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.22719"},{"key":"2020101306300487000_6.3.e001290.9","doi-asserted-by":"publisher","DOI":"10.1177\/0962280206074463"},{"key":"2020101306300487000_6.3.e001290.10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40744-019-00168-5","article-title":"Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA","volume":"6","author":"Radawski","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2020101306300487000_6.3.e001290.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00066.x"},{"key":"2020101306300487000_6.3.e001290.12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.semarthrit.2018.09.003","article-title":"Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts","volume":"48","author":"Baganz","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2020101306300487000_6.3.e001290.13","doi-asserted-by":"crossref","unstructured":"Choi S , Lee KH . Clinical management of seronegative and seropositive rheumatoid arthritis: a comparative study. PLoS One 2018;13:e0195550. doi: 10.1371\/journal.pone.0195550","DOI":"10.1371\/journal.pone.0195550"},{"key":"2020101306300487000_6.3.e001290.14","doi-asserted-by":"crossref","unstructured":"Nordberg LB , Lillegraven S , Aga AB , et al. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR\/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open 2018;4:e000752. doi: 10.1136\/rmdopen-2018-000752","DOI":"10.1136\/rmdopen-2018-000752"},{"key":"2020101306300487000_6.3.e001290.15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-019-2020-x","article-title":"Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort","volume":"21","author":"Lukas","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2020101306300487000_6.3.e001290.16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00393-016-0156-5","article-title":"Medical treatment of rheumatoid arthritis in 2014: current data from the German Collaborative Arthritis Centers","volume":"76","author":"Albrecht","year":"2017","journal-title":"Z Rheumatol"},{"key":"2020101306300487000_6.3.e001290.17"},{"key":"2020101306300487000_6.3.e001290.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2014.11.011"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T13:30:40Z","timestamp":1602595840000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,10,13]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/rmdopen-2020-001290"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001290","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}